ACUT
Price
$0.24
Change
-$0.00 (-0.00%)
Updated
Dec 17 closing price
TELIF
Price
$0.23
Change
-$0.01 (-4.17%)
Updated
Dec 18 closing price
Ad is loading...

ACUT vs TELIF

Header iconACUT vs TELIF Comparison
Open Charts ACUT vs TELIFBanner chart's image
Accustem Sciences
Price$0.24
Change-$0.00 (-0.00%)
Volume$323
CapitalizationN/A
TELESCOPE INNOVATIONS
Price$0.23
Change-$0.01 (-4.17%)
Volume$6K
CapitalizationN/A
ACUT vs TELIF Comparison Chart
Loading...
ACUT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TELIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACUT vs. TELIF commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACUT is a Hold and TELIF is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (ACUT: $0.24 vs. TELIF: $0.23)
Brand notoriety: ACUT and TELIF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACUT: 9% vs. TELIF: 56%
Market capitalization -- ACUT: $2.75M vs. TELIF: $12.25M
ACUT [@Biotechnology] is valued at $2.75M. TELIF’s [@Biotechnology] market capitalization is $12.25M. The market cap for tickers in the [@Biotechnology] industry ranges from $482.1B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACUT’s FA Score shows that 1 FA rating(s) are green whileTELIF’s FA Score has 0 green FA rating(s).

  • ACUT’s FA Score: 1 green, 4 red.
  • TELIF’s FA Score: 0 green, 5 red.
According to our system of comparison, TELIF is a better buy in the long-term than ACUT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACUT’s TA Score shows that 3 TA indicator(s) are bullish while TELIF’s TA Score has 3 bullish TA indicator(s).

  • ACUT’s TA Score: 3 bullish, 5 bearish.
  • TELIF’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both ACUT and TELIF are a bad buy in the short-term.

Price Growth

ACUT (@Biotechnology) experienced а +0.04% price change this week, while TELIF (@Biotechnology) price change was -3.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.11%. For the same industry, the average monthly price growth was -2.34%, and the average quarterly price growth was +0.25%.

Industries' Descriptions

@Biotechnology (-7.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TELIF($12.3M) has a higher market cap than ACUT($2.75M). TELIF YTD gains are higher at: 70.320 vs. ACUT (-61.307). TELIF has higher annual earnings (EBITDA): -436.22K vs. ACUT (-1.74M). TELIF has more cash in the bank: 374K vs. ACUT (9.37K). TELIF has higher revenues than ACUT: TELIF (3.9M) vs ACUT (0).
ACUTTELIFACUT / TELIF
Capitalization2.75M12.3M22%
EBITDA-1.74M-436.22K399%
Gain YTD-61.30770.320-87%
P/E RatioN/A85.38-
Revenue03.9M-
Total Cash9.37K374K3%
Total DebtN/A2.02M-
TECHNICAL ANALYSIS
Technical Analysis
ACUTTELIF
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 3 days ago
73%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 3 days ago
68%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 3 days ago
52%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 3 days ago
48%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 3 days ago
44%
Advances
ODDS (%)
Bullish Trend 16 days ago
74%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 9 days ago
82%
Bearish Trend 16 days ago
70%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 8 days ago
64%
View a ticker or compare two or three
Ad is loading...
ACUT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TELIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VEVYX47.12N/A
N/A
Victory Sycamore Established Value Y
QFVOX22.78-0.13
-0.57%
Pear Tree Polaris Foreign Value Ord
DDICX14.76-0.28
-1.86%
Delaware Wealth Builder C
GPEIX12.01-0.24
-1.96%
Grandeur Peak Emerg Mkts Opps Instl
LUSIX11.46-0.43
-3.62%
Lazard US Systematic Small Cap Eq Ins

TELIF and

Correlation & Price change

A.I.dvisor tells us that TELIF and ATNM have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TELIF and ATNM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TELIF
1D Price
Change %
TELIF100%
-5.43%
ATNM - TELIF
31%
Poorly correlated
-4.92%
RVXCF - TELIF
22%
Poorly correlated
N/A
ENTX - TELIF
20%
Poorly correlated
-1.80%
ACUT - TELIF
11%
Poorly correlated
N/A
REVB - TELIF
9%
Poorly correlated
+1.75%
More